FIELD: medicine.
SUBSTANCE: invention can be used to treat prostate cancer. The following is provided: a method of reducing the plasma concentration of prostate specific antigen (PSA) by at least 50% in a subject with an elevated PSA level, comprising administering to the said subject at least 40 mg of HC-1119, wherein the said subject has prostate cancer being any wild-type androgen receptor (AR) positive prostate cancer and mutant AR positive prostate cancer or non-metastatic castration-resistant prostate cancer (nmCRPC).
EFFECT: invention provides effective treatment of specific forms of prostate cancer.
21 cl, 16 dwg, 2 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HC-1119 COMPOSITION, ITS PRODUCTION METHOD AND USE | 2019 |
|
RU2777008C2 |
| ANDROGEN RECEPTOR SELECTIVE DESTROYING (SARD) LIGANDS AND METHODS OF THEIR USE | 2017 |
|
RU2795431C2 |
| SELECTIVE ANDROGEN RECEPTOR DESTROYING AGENTS (SARD) AND METHODS OF USING THEREOF | 2016 |
|
RU2724103C2 |
| SELECTIVE ANDROGEN RECEPTOR DESTROYING (SARD) LIGANDS AND METHODS OF USING THEM | 2016 |
|
RU2689988C2 |
| METHOD FOR THE TREATMENT OF PRIMARY METASTATIC PROSTATE CANCER | 2022 |
|
RU2796395C1 |
| METHODS OF TREATING ONCOLOGICAL DISEASES | 2011 |
|
RU2589513C2 |
| NEW AUXILIARY THERAPY FOR USE IN THE TREATMENT OF PROSTATE CANCER | 2018 |
|
RU2758386C2 |
| METHODS OF TREATING SOLID TUMORS | 2017 |
|
RU2737934C2 |
| 17ALPHA-BENZOATE OF CORTEXOLONE FOR USE IN TREATING TUMOURS | 2015 |
|
RU2712752C2 |
| MEANS OF TREATMENT AND RELAPSE PREVENTION OF PROSTATE CANCER | 2006 |
|
RU2325160C1 |
